Seizure prophylaxis in pneumococcal meningitis, cohort study.
meningitis
pneumococcal
prophylaxis
seizures
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
25
08
2024
received:
21
03
2024
accepted:
10
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Our aim was to assess seizure development as a complication of pneumococcal meningitis and its possible prevention with antiseizure medication prophylaxis. Antiseizure medication (ASM) prophylaxis has been practiced for a long time at our center. We assessed all cases of community-acquired pneumococcal meningitis admitted from January 2010 to April 2021 recorded in our prospective database and conducted further retrospective studies. Of the 86 cases recorded, 21 (24.4%) developed acute symptomatic seizures, more than half of which (11/21; 52.4%) before admission. Seizure development increased the need for orotracheal intubation and intensive care unit admission, while also lengthening hospital stays and suggesting more risk of death and disability at discharge [adjusted odds ratio (aOR), 3.13; 95% confidence interval (CI): 1-9.8]. Of the 74 patients eligible for ASM prophylaxis, 64 received it and 10 did not. ASM prophylaxis seemed effective in preventing seizure development, as only six seizure events were recorded in 64 patients with ASM prophylaxis (9.4%) compared with four in the 10 patients without prophylaxis (40%). Its preventive capacity was especially notable when administered within 4 h of admission. Differences in mortality did not reach statistical significance. Adverse effects were rare. Seizure development is a common complication in pneumococcal meningitis and is associated with increased risks of Intensive Care Unit admission, orotracheal intubation, and longer hospital stays. ASM prophylaxis may be effective in blocking seizure development in patients with preventable seizures and may be associated with better prognosis. Further studies are now warranted. Infection of the meninges (the covering of the brain) due to the common bacteria S pneumoniae, used to be a fatal disease before the introduction of antibiotics and corticoids. Thanks to these drugs, more people survive this disease but, due to the frequent complications, they may have several sequelae. Seizures are a common complication. Our study suggests that they might be prevented by using antiseizure drugs which may reduce both severity and hospital stay.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID study Group for Infections of the brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37–S62. https://doi.org/10.1016/j.cmi.2016.01.007
Centers for Disease Control and Prevention. 2018. Active bacterial Core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2018. Available via the internet: http://www.cdc.gov/abcs/reports‐findings/survreports/spneu18.pdf. Accessed 8 May 2023
Koelman DLH, Brouwer MC, Ter Horst L, Bijlsma MW, van der Ende A, van de Beek D. Pneumococcal meningitis in adults: a prospective Nationwide cohort study over a 20‐year period. Clin Infect Dis. 2022;74(4):657–667. https://doi.org/10.1093/cid/ciab477
van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849–1859. https://doi.org/10.1056/NEJMoa040845
Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 2006;5(2):123–129. https://doi.org/10.1016/S1474‐4422(05)70288‐X
de Gans J, van de Beek D. European dexamethasone in adulthood bacterial meningitis study investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549–1556. https://doi.org/10.1056/NEJMoa021334
Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;2015(9):CD004405. https://doi.org/10.1002/14651858.CD004405.pub5
Wall EC, Ajdukiewicz KM, Bergman H, Heyderman RS, Garner P. Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database Syst Rev. 2018;2(2):CD008806. https://doi.org/10.1002/14651858.CD008806.pub3
Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain. 2003;126(Pt 5):1015–1025. https://doi.org/10.1093/brain/awg113
Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11–21. https://doi.org/10.1016/j.expneurol.2011.09.033
Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671–675. https://doi.org/10.1111/j.1528‐1167.2009.02285.x
Haapaniemi E, Strbian D, Rossi C, Putaala J, Sipi T, Mustanoja S, et al. The CAVE score for predicting late seizures after intracerebral hemorrhage. Stroke. 2014;45(7):1971–1976. https://doi.org/10.1161/STROKEAHA.114.004686
Hui AC, Tang A, Wong KS, Mok V, Kay R. Recurrence after a first untreated seizure in the Hong Kong Chinese population. Epilepsia. 2001;42(1):94–97. https://doi.org/10.1046/j.1528‐1157.2001.99352.x
Zoons E, Weisfelt M, de Gans J, Spanjaard L, Koelman JHTM, Reitsma JB, et al. Seizures in adults with bacterial meningitis. Neurology. 2008;70(22 Pt 2):2109–2115. https://doi.org/10.1212/01.wnl.0000288178.91614.5d
Larsen FTBD, Brandt CT, Larsen L, Klastrup V, Wiese L, Helweg‐Larsen J, et al. Risk factors and prognosis of seizures in adults with community‐acquired bacterial meningitis in Denmark: observational cohort studies. BMJ Open. 2019;9(7):e030263. https://doi.org/10.1136/bmjopen‐2019‐030263
Cabellos C, Verdaguer R, Olmo M, Fernández‐Sabé N, Cisnal M, Ariza J, et al. Community‐acquired bacterial meningitis in elderly patients: experience over 30 years. Medicine (Baltimore). 2009;88(2):115–119. https://doi.org/10.1097/MD.0b013e31819d50ef
Wang KW, Chang WN, Chang HW, Chuang YC, Tsai NW, Wang HC, et al. The significance of seizures and other predictive factors during the acute illness for the long‐term outcome after bacterial meningitis. Seizure. 2005;14(8):586–592. https://doi.org/10.1016/j.seizure.2005.09.004
Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;15(168):107966. https://doi.org/10.1016/j.neuropharm.2020.107966
Cabellos C, Guillem L, Pelegrin I, Tubau F, Ardanuy C, Gudiol F, et al. Penicillin‐ and cephalosporin‐resistant pneumococcal meningitis: treatment in the real world and in guidelines. Antimicrob Agents Chemother. 2022;66(12):e0082022. https://doi.org/10.1128/aac.00820‐22
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1(7905):480–484. https://doi.org/10.1016/s0140‐6736(75)92830‐5
Noachtar S, Binnie C, Ebersole J, Mauguière F, Sakamoto A, Westmoreland B. A glossary of terms most commonly used by clinical electroencephalographers and proposal for the report form for the EEG findings. The international federation of clinical neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999;52:21–41.
Hirsch LJ, LaRoche SM, Gaspard N, et al. American clinical neurophysiology Society's standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. 2013;30(1):1–27. https://doi.org/10.1097/WNP.0b013e3182784729
Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58(4):531–542. https://doi.org/10.1111/epi.13671
Leitinger M, Beniczky S, Rohracher A, Gardella E, Kalss G, Qerama E, et al. Salzburg consensus criteria for non‐convulsive status epilepticus‐approach to clinical application. Epilepsy Behav. 2015;49:158–163. https://doi.org/10.1016/j.yebeh.2015.05.007
Bohr V, Rasmussen N, Hansen B, Gade A, Kjersem H, Johnsen N, et al. Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and on a study of lasting sequelae. J Infect. 1985;10(2):143–157. https://doi.org/10.1016/s0163‐4453(85)91585‐3
Lanzino G, D'Urso PI. Suarez J; participants in the international multi‐disciplinary consensus conference on the critical Care Management of Subarachnoid Hemorrhage. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15(2):247–256. https://doi.org/10.1007/s12028‐011‐9584‐x
Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta‐analysis of controlled trials. Epilepsia. 2001;42(4):515–524. https://doi.org/10.1046/j.1528‐1157.2001.28900.x
Farrokh S, Tahsili‐Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA. Antiepileptic drugs in critically ill patients. Crit Care. 2018;22(1):153. https://doi.org/10.1186/s13054‐018‐2066‐1
Yerram S, Katyal N, Premkumar K, Nattanmai P, Newey CR. Seizure prophylaxis in the neuroscience intensive care unit. J Intensive Care. 2018;5(6):17. https://doi.org/10.1186/s40560‐018‐0288‐6
Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, Fourth edition. Neurosurgery. 2017;80(1):6–15. https://doi.org/10.1227/NEU.0000000000001432
Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double‐blind study of phenytoin for the prevention of post‐traumatic seizures. N Engl J Med. 1990;323(8):497–502. https://doi.org/10.1056/NEJM199008233230801
Jones FJS, Sanches PR, Smith JR, Zafar SF, Blacker D, Hsu J, et al. Seizure prophylaxis after spontaneous intracerebral hemorrhage. JAMA Neurol. 2021;78(9):1128–1136. https://doi.org/10.1001/jamaneurol.2021.2249
Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert‐Bast S, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58(6):933–950. https://doi.org/10.1111/epi.13716
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103–2113. https://doi.org/10.1056/NEJMoa1905795
Veran O, Kahane P, Thomas P, Hamelin S, Sabourdy C, Vercueil L. De novo epileptic confusion in the elderly: a 1‐year prospective study. Epilepsia. 2010;51(6):1030–1035. https://doi.org/10.1111/j.1528‐1167.2009.02410.x